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Abstract
Objectives. Apolipoprotein A-1 (ApoA-1) is a protein fraction of the high-density lipoproteins with anti-inflammatory and
antioxidant properties that play a major role in reverse cholesterol transport. The presence of anti-ApoA-1 IgG has been
reported in SLE to be variably associated with disease activity or cardiovascular events (CVEs). We assessed the clinical
performance of anti-ApoA-1 IgG and of antibodies directed against its immunodominant F3L1 peptide (F3L1 IgG) in a
well-characterized Swiss SLE cohort study.
Methods. A total of 354 biological samples and interviews from 176 individuals were studied. SLEDAI, clinical char-
acteristics, anamnestic CVEs and therapy details were recorded. Sera were tested for the presence of anti-ApoA-1 IgG,
anti-F3L1 IgG, anti-dsDNA IgG and aPL.
Results. Anti-ApoA-1 and anti-F3L1 IgG positivity was associated with higher SLEDAI, mostly due to concomitant
positivity of dsDNA IgG and low complement. Variations in time of anti-ApoA-1 IgG correlated positively with variations of
anti-dsDNA IgG and inversely to variations of C3 levels. No cross-reactivity was found between anti-ApoA-1 and anti-
dsDNA IgG. Positivity for anti-Apo-A1 IgG was more frequent in individuals receiving 10 mg/day or more of prednisone.
We did not find any significant association between anti-ApoA-1 IgG positivity and CVEs.
Conclusion. Anti-ApoA-1 and anti-F3L1 IgG in SLE correlate strongly with laboratory markers of activity, particularly
with the presence and titre of dsDNA IgG. These results confirm and extend previous findings and support the use of anti-
ApoA1 IgG in the clinical setting. Their role in CVEs deserves further investigation.
Key words: systemic lupus erythematosus, SLEDAI, anti-apolipoprotein-A1 antibody, anti-F3L1 antibody, anti-
dsDNA antibody, anti-phospholipids antibody, biomarker, cardiovascular events
Rheumatology key messages
. Anti-ApoA-1 and anti-F3L1 IgG are frequently present in SLE.
. Anti-ApoA-1 and anti-F3L1 IgG correlate with SLEDAI and anti-dsDNA antibodies in SLE.
. Anti-ApoA-1 and anti-F3L1 IgG antibodies are not associated with cardiovascular events in the Swiss SLE cohort
study.
Introduction
SLE is an autoimmune disease characterized by loss of
tolerance towards self-components and the generation of
a wide variety of autoantibodies (Abs) directed against
ubiquitous as well as organ-specific auto-antigens [1].
However, the extent to which Abs are involved in disease
progression and organ damage remains subject to debate
[1]. Significantly, SLE clinically progresses through flares
and remissions, and biomarkers associated with disease
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activity may be clinically useful in identifying patients at
risk of disease exacerbations [2]. Furthermore, in SLE,
morbidity and mortality are not only associated with
organ involvement, but also with cardiovascular events
(CVEs), particularly in young individuals [3].
Apolipoproteins are the most important protein compo-
nents of amphipathic lipoproteins transporting lipids in
the blood. Among them, apolipoprotein A-1 (ApoA-1) is
the major protein fraction of high-density lipoproteins,
which play a key role in reverse cholesterol transport
and are endowed with substantial anti-inflammatory and
antioxidant properties, thereby exercising a protective role
in the cardiovascular system [4, 5]. Notably, Abs directed
against ApoA-1 were initially described in patients with
SLE and the aPL syndrome [68]. The literature has
since expanded, illustrating their potential role as risk fac-
tors in the development of CVEs, both in diseases with an
auto-immune background (such as RA [9]) and in other
pathological contexts, particularly coronary heart disease
[1013]. They have also been found in the general popu-
lation, where these antibodies have been reported to rep-
resent an independent CVE risk factor [14] associated
with increased mortality, susceptibility polymorphisms
and incident coronary events [15, 16], although this has
recently been disputed [17].
Moreover, two immunodominant epitopes were identi-
fied in ApoA-1, and a synthetic, stable peptide, named
F3L1, which mimics a portion of the C-terminal alpha-
helix, is preferentially recognized by Abs in individuals
with CVEs [18, 19].
When studied in SLE, anti-ApoA-1 Abs (anti-ApoA-1
IgG) have been variably associated with disease activity.
It is still debated whether or not their presence is asso-
ciated with CVEs [2024], and no data are available on
anti-F3L1 antibodies in SLE. We revisited these issues
through the lens of the well-characterized, nationwide,
multicentric, transdisciplinary Swiss SLE Cohort Study
[25].
Methods
Patient cohort
Serum samples were obtained from 176 individuals sat-
isfying at least four ACR SLE criteria and consecutively
enrolled in the prospective Swiss SLE Cohort Study
from April 2007 to January 2015 [25]. Follow-up samples
were collected yearly (a total of 354 distinct samples), and
these were processed in a single laboratory in Geneva.
Disease activity was captured by Safety of Estrogens
in Lupus Erythematosus National Assessment (SELENA)-
SLEDAI [26], with organ involvement and medication
recorded at each study visit [25]. The controls were age-
and sex-matched healthy individuals donating blood at
the Transfusion Centre of the University Hospital in
Geneva. Ethical clearance was granted in all participating
Swiss SLE Cohort Study centres. Informed, written con-
sent was obtained from all participants in accordance with
the Declaration of Helsinki.
Determination of human antibodies to ApoA-1/F3L1
by ELISA
Anti-ApoA-1 and anti-F3L1 IgG serum levels were as-
sessed as previously described [10, 11, 27]. All samples
were tested in duplicates. An index consisting of the ratio
between sample absorbance and a standard positive con-
trol absorbance 100 was calculated. Sera from 48
healthy donors served to define the threshold for positivity
of anti-ApoA-1 IgG and for anti-F3L1 IgG. The value cor-
responding to the 97.5th percentile of the normal distribu-
tion gave an IgG index of 42 for anti-ApoA-1 and 37 for
anti-F3L1. Accordingly, samples tested for anti-ApoA-1
were considered positive when their index was 542,
and samples tested for anti-F3L1 were considered posi-
tive when 537.
Determination of antibodies to dsDNA by ELISA
Anti-dsDNA serum levels were measured by ELISA using
a commercially available method (QUANTA Lite dsDNA,
Inova Diagnotics, San Diego, CA), according to the sup-
plier’s instructions, in a single laboratory in Geneva
(Laboratory of Immunology and Allergy, University
Hospital, Switzerland). The threshold of positivity was
200 U.
Determination of aPL
Lupus anticoagulant was detected using ACL TOP (IL,
France), which detected the ability to prolong the
phospholipid-dependent DRVVT test. The presence and
titre of aCL, anti-b2 glycoprotein 1 (anti-b2GP1) IgG and
aPS-PT IgG was assessed using the HemosIL AcuStar
Coagulation Analyzer (Instrumentation Laboratory,
Bedford, MA) [28]. The cut-off values for these tests
were based on the 99th percentile and the corresponding
95% confidence interval for each antibody of 626 healthy
Blood Bank donors. All the assays were performed in a
single laboratory in Geneva (Hemostasis Unit, University
Hospital, Switzerland).
Competition ELISA to test the cross-reactivity of anti-
ApoA-1 Ab
Sera of patients known to be highly positive for anti-ApoA-
1 IgG, anti-b2GP1 IgG and anti-dsDNA IgG were pre-incu-
bated for 2 h at room temperature with or without different
competitors: F3L1 (Geneva University, Switzerland),
b2GP1 (Haematologic Technologies Inc., USA) and
dsDNA (Inova Diagnostics, USA) at three concentrations
prior to addition to wells coated with ApoA-1. Anti-Apo-A1
IgG were then assessed according to standard protocol.
Tests were performed in triplicate. Percentage maximal
ELISA signals were calculated as 100  {[signal in well]-
[mean background signal (uncoated well)]}/{[mean max-
imal signal (no competing peptide)][mean background
signal]}.
Statistical analysis
To compare groups according to anti-ApoA-1 IgG status,
we used the Fisher’s exact, 2 tests for categorical vari-
ables, the MannWhitney test for continuous variables. To
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compare groups’ characteristics at baseline and at the
1 year assessment, we used McNemar’s test and the de-
pendent t test. Spearman correlations were used for
bivariable association. For multivariable association, we
used multilevel regression with random intercept to ac-
count for the repeated measures per individual.
Statistical analysis was performed by using SPSS
Statistics

version 25 from IBM Corp. Armonk, NY USA,
and Prism

version 7 from Graphpad Software Inc,
San Diego, California.
Results
Clinical characteristics of anti-ApoA-1 IgG+ and anti-
F3L1 IgG+ SLE patients
This cohort was composed of 176 SLE individuals. Their
mean age at inclusion was 44 years (15) [range 1785],
85% were women, and 78% were of Caucasian origin.
The mean age at SLE diagnosis was 35 years (15) [range
1273]. Of the 176 included SLE patients, 104 individuals
contributed an additional sample after 1 year; 47 after
2 years; 20 after 3 years; 6 after 4 years and 1 after
5 years. Anti-ApoA-1 IgG Abs were detected in 76 (43%)
initial samples of the 176 patients. The main clinical char-
acteristics, distribution of ACR criteria, as well as treat-
ment at inclusion are reported in Table 1. In general, no
major clinical differences were observed when anti-ApoA-
1 IgG+ and anti-ApoA-1 IgG individuals were compared,
with the exception of younger age at first assessment
[42 (15) years in anti-ApoA-1 IgG+, vs 46 (14) years in
anti-ApoA-1 IgG, P=0.048] and lower frequency of seiz-
ures in anti-ApoA-1 IgG+ (12% in anti-ApoA-1 IgG and
3% in anti-ApoA-1 IgG+, P=0.025). Notably, however, the
frequency of individuals historically positive for aPL, and
the frequency of individuals under anti-platelet agents,
were both statistically higher in anti-ApoA-1 IgG+ com-
pared with anti-ApoA-1 IgG individuals. Thus, 62% vs
37% (P < 0.001) were positive for aPL and 29% vs 13%
(P < 0.001) were under anti-platelets agents in anti-ApoA-
1 IgG+ and anti-ApoA-1 IgG, respectively. All sera were
also tested for anti-F3L1 antibodies, and 39 patients
(22%) were positive at first assessment, with a moderate
agreement with anti-ApoA-1 IgG positivity (kappa coeffi-
cient=0.348; P < 0.05). However, anti-ApoA-1 and anti-
F3L1 antibodies titres were highly correlated (Spearman
coefficient=0.66, P < 0.001). At inclusion, in accordance
with associations found with anti-ApoA-1 IgG+, the anti-
F3L1 IgG positive compared with negative individuals
were more likely to be positive for aPL (74% vs 40%, P
< 0.001). Other items at inclusion did not differ signifi-
cantly according to the anti-F3L1 IgG status (Table 1).
‘Total cholesterol and triglycerides levels were available
in 123 individuals, of which 18 were under statin treat-
ment. Total cholesterol and triglyceride levels were not
different in anti-ApoA-1 IgG positive vs negative patients,
regardless of whether they were receiving lipid-lowering
drugs or antimalarials.’
Intergroup difference in SLE treatments
Anti-ApoA-1 IgG+ showed a trend for higher frequency of
use of CSs at inclusion, although this was not significant
(Table 1). However, we demonstrated a significantly
higher frequency of anti-ApoA-1 among patients grouped
by CSs treatment categories <10 mg/day or >10 mg/day
(P=0.04), in accordance with previous data [24]. No sig-
nificant difference was found when comparing anti-ApoA-
1 IgG+ and anti-ApoA-1 IgG groups for antimalarial
agents, immunosuppressant agents, NSAIDs, lipid-lower-
ing drugs or anti-coagulant use (Table 1).
Association between anti-ApoA-1 IgG/anti-F3L1 IgG
and parameters of disease activity in SLE
SLEDAI was slightly but statistically significantly higher
in anti-ApoA-1 IgG+, with a median of 6 points (inter-
quartile range 210) compared with 4 points (interquar-
tile range 08) in anti-ApoA-1 IgG individuals, P=0.028.
This was also observed when comparing anti-F3L1 IgG+
and anti-F3L1 IgG individuals, P=0.025 (Table 2). While
there was a trend for an association between anti-ApoA-
1 IgG+ and arthritis (26% vs 16%, P=0.093), no other
clinical items captured by SLEDAI were associated with
anti-ApoA-1 IgG positivity. However, a number of la-
boratory items were more frequently abnormal in anti-
ApoA-1 IgG+ compared with in anti-ApoA-1 IgG indi-
viduals. These included the presence of haematuria,
proteinuria, leukopoenia and anti-dsDNA Abs, and
lower levels of complement C3 and C4. Similarly, anti-
F3L1 IgG+ compared with anti-F3L1 IgG individuals
had significantly higher anti-dsDNA IgG titres, and
lower complement levels for both C3 and C4 (Table 2).
To foster these observations, we then assessed whether
there was a correlation between the titre of anti-ApoA-1
IgG and the titre of anti-dsDNA Abs, and with the C3 and
C4 serum levels, in all longitudinal samples that were
available (n = 354). A positive correlation was observed
with anti-dsDNA Abs, and a negative correlation with C3
and C4 serum levels (Fig. 1A). Notably, the correlation
was lower when the contribution of complement con-
sumption was excluded from the SLEDAI, and was not
any more significant when both the contribution of anti-
dsDNA antibodies’ positivity and complement con-
sumption were excluded (Fig. 1B). Similar results
were found for anti-F3L1 IgG, which showed a positive
correlation with anti-dsDNA (n = 348, Spearman
rho = 0.412, P < 0.001) and a negative correlation
with C3 (rho=0.299, P < 0.001) and C4 (rho=0.252,
P < 0.001) (Fig. 1C). There was a correlation with
SLEDAI (rho = 0.174, P=0.001), which was still signifi-
cant when complement consumption was removed
from the SLEDAI (P=0.014), but which lost significance
when both anti-dsDNA and complement consumption
were removed from the score (P=0.352) (Fig. 1D).
Multiple regression analysis
When using multiple regression analysis, both the con-
tribution of anti-ApoA-1 and anti-F3L1 antibodies to
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SLEDAI lost significance when adjusted for anti-dsDNA
(P=0.85 for anti-ApoA-1 IgG and P=0.26 for anti-F3L1
IgG), which may be explained by the strong correlation
between anti-dsDNA and anti-ApoA-1 or anti-F3L1
titres.
Covariation over time of anti-ApoA-1/F3L1 IgG titres
with anti-dsDNA IgG titres
Given the positive correlation between anti-ApoA-1/anti-
F3L1 IgG and anti-dsDNA IgG observed in the 354 samples
available, we then assessed whether variations in time in
FIG. 1 Correlation between anti-ApoA-1 IgG/anti-F3L1 IgG and parameters of SLE disease activity
Correlation between anti-ApoA-1 IgG levels and biological parameters of SLE disease activity (A) or SELENA-SLEDAI (B)
as well between anti-F3L1 IgG levels and biological parameters of SLE disease activity (C) or SELENA-SLEDAI (D) were
calculated. DsDNA IgG was determined by ELISA, C3 and C4 determined by nephelometry, all assessed at the time of
sample. Rho was computed according to the Spearman test; the red line shows bivariate linear regression. ApoA-1:
apolipoprotein A-1; SELENA: Safety of Estrogens in Lupus Erythematosus National Assessment.
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the titre of anti-ApoA-1 IgG were associated with similar
changes in the titre of anti-dsDNA Abs, taking into account
the cohort samples obtained at inclusion and 1 year apart
(n= 104). The clinical characteristics of the individuals stu-
died 1 year apart were similar to data at inclusion (not
shown). Interestingly, the variations in time in the titre of
anti-ApoA-1 IgG+ were statistically associated with vari-
ations in the titre of anti-dsDNA IgG (Table 3). Similar ana-
lyses conducted with complement C3 and C4 levels
indicated significant negative association of anti-ApoA-1
IgG with C3, albeit to a lower level of statistical significance,
and a trend for negative association, not statistically signifi-
cant, for C4. Very similar data were observed for anti-F3L1
IgG (Table 3). Thus, the titre of anti-ApoA-1/F3L1 IgG ap-
pears to be exquisitely correlated with the titre of anti-
dsDNA IgG and its variation over time.
Association of anti-ApoA-1/F3L1 IgG with aPL
As reported in Table 1, the historic frequency of aPL Abs
(ACR criteria) was higher in anti-ApoA-1 IgG+ than in anti-
ApoA-1 IgG. To better characterize this association, we
tested the very same inclusion serum samples for which
anti-ApoA-1 IgG were assessed for the presence of aCL
IgG, anti-b2GP1 IgG, aPS-PT IgG and DRVVT [28]. The fre-
quency of aCL IgG+ (32% vs 12%, P=0.001), anti-b2GP1
IgG+ (33% vs 14%, P=0.003), aPS-PT IgG (22% vs 12%,
P=0.066) and the positivity of DRVVT (36% vs 13%, P <
0.001) were higher in anti-ApoA-1 IgG+ than in anti-ApoA-1
IgG sera. When such associations were searched for anti-
F3L1 reactivity, only aPS-PT IgG was significantly more fre-
quent in anti-F3L1 IgGpositive than anti-F3L1 IgGnegative
samples (28% vs 13%, P=0.025) (not shown).
No cross-reactivity between anti-ApoA-1 and
anti-dsDNA IgG revealed by competition ELISA
Given the correlations observed between anti-ApoA-1,
anti-dsDNA and anti-b2GP1 IgG, we tested whether
cross-reactivity could explain, at least in part, our findings
by performing competition assays. Using a triple positive
serum for anti-ApoA-1, anti-b2GP1 and anti-dsDNA IgG,
we observed that F3L1 did inhibit dose-dependently the
anti-ApoA-1 reactivity. In the same assay, dsDNA did not
inhibit, while b2GP1 was partially inhibitory (Fig. 2).
Conversely, dsDNA, but not F3L1, inhibited anti-dsDNA
reactivity, and b2GP1, but not F3L1, inhibited anti-
b2GP1 reactivity (Supplementary Fig. S1, available at
Rheumatology online). Thus, the correlation that we
observed between anti-ApoA-1 and anti-dsDNA IgG
titres was not due to cross-reactivity of the sera.
Anti-ApoA-1 IgG, anti-F3L1 IgG positivity and
arterio-venous thrombo-embolic vascular events
Previous reports in pathological conditions other than
SLE, as well as in the general population, have
FIG. 2 Cross-reactivity between anti-ApoA-1 and other
auto-antibodies
The serum of a representative patient of four tested,
known to be positive for anti-ApoA-1 IgG, anti-b2GP1 IgG
and anti-dsDNA IgG, was pre-incubated with or without
the various competitors (F3L1, b2GP1 and dsDNA) at the
indicated concentrations prior to addition to assay wells
for anti-ApoA1 IgG measurement. Percentage maximal
ELISA signals were calculated as 100{[signal in well]-
[mean background signal (uncoated well)]}/{[mean max-
imal signal (no peptide)][mean background signal]}.
Results are expressed as mean (S.D.) (n =3). ApoA-1:
apolipoprotein A-1.
TABLE 3 Covariation in time of anti-ApoA-1/anti-F3L1 IgG and anti-dsDNA IgG titres, complement C3 and C4
" SLEDAI " anti-dsDNA IgG " C3 " C4
 anti-ApoA-1 IgG n 104 104 77 77
Spearman rho 0.114 0.341 0.228 0.188
P value 0.248 <0.001 0.046 0.101
 anti-F3L1 IgG n 101 100 74 74
Spearman rho 0.169 0.459 0.213 0.173
P value 0.091 <0.001 0.068 0.141
=difference in the titre of the parameter in two samples of the same individual taken 1 year apart. Significant P values are
shown in bold text. ApoA-1: apolipoprotein A-1.
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documented an association between the presence of anti-
ApoA-1 IgG and CVEs. Therefore, we assessed whether
this was the case in our cohort. Arterial and venous vas-
cular events were frequent in our study population, with an
overall prevalence of 21%, of which 20 were venous, 22
arterial, and 37 either venous or arterial. There was no
statistically significant difference in the frequency of
CVEs between anti-ApoA-1 IgG+ and IgG groups, or be-
tween anti-F3L1 IgG+ and IgG groups (Table 4).
Discussion
The results here reported confirm and extend previous
findings, by highlighting a striking association of anti-
ApoA-1 IgG with anti-dsDNA antibody levels, with other
laboratory parameters of disease activity and with steroid
dose as shown previously [24], supporting a role for anti-
ApoA-1 IgG as a laboratory marker of SLE activity, and
suggesting that anti-ApoA-1 IgG may participate in SLE
pathogenesis. In addition, we show for the first time that
anti-F3L1 Abs correlate with disease activity and anti-
dsDNA Abs in SLE patients. Remarkably, we found an
association of anti-ApoA-1 IgG with aPL antibodies but
not with CVEs.
Previous publications highlighted the link between anti-
ApoA-1 IgG and SLE activity when assessed by SLEDAI,
ECLAM and BILAG scores [20, 2224, 29]. We confirm
here that anti-ApoA-1 IgG correlates with SELENA-
SLEDAI. However, we found that the laboratory items of
SELENA-SLEDAI, in particular the presence of anti-
dsDNA IgG and lower levels of complement C3 and C4,
were more frequent in anti-ApoA-1 IgG+ and anti-F3L1
IgG+ compared with anti-ApoA-1/F3L1 IgG negative.
Our data highlight in particular the relationship between
the presence and titre of anti-ApoA-1 IgG and anti-dsDNA
IgG at inclusion, and the correlation between their titre
variations over time. The multiple regression analysis
showed that anti-dsDNA IgG rather than anti-ApoA-1
IgG explained the association with disease activity.
However, we could not find cross-reactivity in a competi-
tion ELISA, which supports a biologically independent role
of anti-ApoA-1 IgG. Consistently, a correlation of anti-
ApoA-1 IgG with anti-dsDNA IgG was reported in patients
with active lupus nephritis [22], not observed by others [8,
23, 24]. The discrepancies may be explained by technical
differences characterizing the assays used to detect anti-
dsDNA IgG and anti-ApoA-1 IgG. In particular, the ELISA
we used to assess the presence of anti-dsDNA IgG may
be more sensitive than the Farr assay used by others
[22, 24].
Along the same lines, it is noteworthy that in our cohort
the titre of anti-ApoA-1 IgG was in inverse correlation
with complement C3 and C4 levels, as already reported
[23]. Similar trends were observed for anti-F3L1 IgG.
Furthermore, we show an inverse covariance with time
in C3 and C4 titres that reinforces the contention that
anti-ApoA-1 IgG may take part in important immunologic
events in SLE pathogenesis. In this respect, it is import-
ant to stress that ApoA-1 is known to potentially interact
with several self-components, some of which are deco-
rated with danger-associated molecular patterns. Thus,
we could speculate that some of these interactions
would favour anti-ApoA-1 autoimmune responses
fluctuating consensually with dsDNA antibody titres and
inversely with C3 and C4 and accompanying SLE dis-
ease activity. The full range of known ApoA-1 inter-
actions with other self-components can be found in
BioGRID3.5. [30].
An interesting finding in our study was the association
between anti-ApoA-1 IgG and aPL Abs. In addition, the
use of anti-platelet agents was significantly more frequent
in our anti-ApoA-1 IgG+ population, possibly in relation to
the frequent use of low-dose aspirin in individuals positive
for aPL but not having experienced thrombotic events [31,
32]. Although some of the previous studies on anti-ApoA-
1 IgG in SLE have not found an association with aPL Abs
[22, 23], the potential interaction between aCL IgG and
anti-ApoA-1 IgG was suggested by studies showing
decreased levels of apolipoprotein A1 in individuals posi-
tive for aCL Abs [33]. However, our findings indicate a
slight inhibition of anti-ApoA-1 IgG reactivity when com-
peted with b2GP1 protein, suggesting potential cross-re-
activity with aPL Abs, in agreement with Delgado et al.
[34].
In various pathological conditions [10, 11, 35], as well as
in the general population [15, 16], the presence of anti-
ApoA-1 IgG has been associated with an increased risk of
CVEs. This association has recently been questioned [17].
In agreement with three previous reports on SLE patients
[22, 24], our results did not reveal an association between
the presence of anti-ApoA-1 IgG and arterial or venous
vascular events in SLE. This lack of an association is
even more surprising given the correlation in the titres of
TABLE 4 Presence of anti-ApoA-1 and anti-F3L1 IgG is not associated with arterial or venous vascular events
All
(N= 176)
Anti-ApoA-1
IgG  (N= 100)
Anti-ApoA-1
IgG + (N= 76) P-value
Anti-F3L1
IgG 
(N= 137)
Anti-F3L1
IgG +
(N= 39) P-value
Arterial events, no. (%) 20 (11) 12 (12) 8 (11) 0.760 28 (20) 9 (23) 0.824
Venous events, no. (%) 22 (13) 11 (11) 11 (14) 0.490 18 (13) 2 (5) 0.252
Arterial or venous events, no. (%) 37 (21) 20 (20) 17 (22) 0.702 15 (11) 7 (18) 0.274
2 test (n>10) or Fisher test (n< 10) were used to compare groups. ApoA-1: apolipoprotein A-1.
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aPL Abs with anti-ApoA-1 IgG, and the frequent associ-
ation of aPL Abs with CVEs [36]. However, the overall low
number of CVEs in our cohort (n= 37) may represent a
serious limitation for the interpretation of these data.
Furthermore, the high frequency of patients in our cohort
simultaneously taking low-dose aspirin and HCQ may
have had an impact on CVE risk. Indeed, it has been re-
cently observed that this therapeutic combination has
additive effects in the primary prevention of CVEs in SLE
[37, 38]. It is important to stress that, in the very same
Swiss SLE cohort, we found that CVEs were associated
with the presence of lupus anticoagulant and anti-phos-
phatidylserine/prothrombin complex IgG [28].
In our study, the frequency of anti-F3L1 IgG positive
sera were about half of our ApoA1 IgG samples, in ac-
cordance with previous studies [18, 19]. While precise
immunomapping of ApoA-1 was not performed with SLE
sera, in our study anti-F3L1 IgG, similarly to anti-ApoA-1
IgG, were associated with SLE activity markers: SELENA-
SLEDAI, dsDNA antibodies, and low complement.
Furthermore, anti-F3L1 IgG have been reported to be
associated with CVEs in individuals without autoimmune
diseases [18], a finding that we could not replicate in our
SLE cohort. Anti-ApoA-1 IgG in SLE may trigger biological
responses qualitatively different from those observed in
other conditions. Indeed, anti-ApoA-1 IgG have been
shown to interact with TLR2 and 4 and recruit CD14 in
the context of atherothrombosis [3941]. Whether this is
the case in SLE requires experimental enquiry. Thus, anti-
ApoA-1 and anti-F3L1 IgG do not appear to be associated
with CVEs in a cohort in which classical and novel aPL
were studied.
There are several limitations in our study. First, the
number of individuals included in the cohort at study ini-
tiation decreased during follow-up, leading to a risk of
selection bias. However, the frequency of positive sam-
ples for anti-ApoA-1 IgG as well as disease activity were
not different when compared at inclusion and 1 year later
(Supplementary Tables S1 and S2 and Supplementary
Fig. S2, available at Rheumatology online). Second, this
is not an inception cohort, and most thrombotic events
were recorded by review of the clinical charts. Others
have found that thrombotic events accumulate over time
[42]. It is possible that the prospective follow-up of our
cohort would reveal an association with anti-ApoA-1
IgG. Third, within the anti-ApoA-1 antibody repertoire,
we did not test for isotypes other than IgG, thus limiting
the potential for detecting important clinical associations.
In conclusion, anti-ApoA-1 IgG are present in a sizable
proportion of SLE individuals, and their presence correl-
ates strongly with the presence of anti-dsDNA IgG, with
other SLE biomarkers associated with disease activity and
with high steroid use. In contrast with the analysis in other
populations, but consistent with previous reports in SLE,
our data do not indicate that anti-apoA-1 IgG nor anti-
F3L1 IgG are associated with CVEs in SLE. Therefore,
the possible clinical relevance of anti-apoA-1 IgG in SLE
may be of greater interest in better capturing patients at
risk of more active SLE disease, than in identifying SLE
patients at higher CVE risk. These data suggest that the
routine identification of anti-ApoA-1 IgG may be a useful
adjunct for monitoring SLE.
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